Compounded semaglutide and Wegovy contain the same active ingredient, but they are not the same product, and the price gap between them reflects that. Wegovy is an FDA-approved injection with a label, a fixed dose schedule and a maker’s self-pay price[1][2]. A compounded version is mixed by a pharmacy for an individual prescription, and FDA does not review it for safety, effectiveness or quality before it is sold[3].
Both are semaglutide injected once a week, so the comparison below keeps the unit the same: one month of injections.
The two prices, in one unit
$349
Wegovy pen, self-pay, one box of 4 pens (28 days)
Source: Wegovy Savings Offer terms
$199
Wegovy pen, first 2 fills for new self-pay patients
Source: Wegovy Savings Offer terms
$187
Typical compounded semaglutide injection month (380 sellers)
Compounded injection prices run from $76 to $485 a month across 380 sellers, read through September 2026. Wegovy’s self-pay figures come from the maker’s offer terms, read in September 2026[2].
The Wegovy self-pay price covers one box of 4 single-dose pens, a 28-day supply, at every dose from 0.25 mg to 2.4 mg, and the 7.2 mg Wegovy HD pen costs $399[2]. New self-pay patients pay $199 for each of their first 2 fills at the two starting doses, an offer that runs through December 2026[2]. The full ladder, the HD pen and the card are covered in Wegovy cost, and the compounded market by dose is in compounded semaglutide cost.
A seller’s monthly figure is rarely the whole bill, because membership, consult and shipping fees often sit beside it. The all-in monthly calculator adds those lines, and the semaglutide all-in board orders sellers by the month a buyer actually pays, compounded and branded together. Drops and dissolving tablets are a different product, priced in sublingual semaglutide.
What the approval stands for
The Wegovy label rests on trials of the approved product. In the STEP 1 trial, 1,961 adults with obesity, or overweight with a weight-related condition, and without diabetes took 2.4 mg of semaglutide or placebo once a week for 68 weeks alongside lifestyle intervention[5]. Mean body weight fell by 14.9% on semaglutide against 2.4% on placebo[5].
Those results describe the approved drug at the label’s doses. No trial of that size has tested a compounded semaglutide product, so a compounded seller’s product borrows the evidence rather than having its own.
Why compounded semaglutide narrowed after 2025
Pharmacies were able to make copies of the approved injection widely while it was in shortage. FDA determined on February 21, 2025, that the semaglutide injection shortage was resolved[4]. It then set the dates after which it would no longer hold back enforcement against copies: April 22, 2025, for 503A pharmacies and May 22, 2025, for 503B outsourcing facilities[4].
A 503A pharmacy may still compound for an individual patient’s prescription, but it may not regularly or in inordinate amounts make products that are essentially copies of a commercially available drug[4]. FDA gives adding vitamin B12 to semaglutide as an example of a product it may still consider essentially a copy, unless the prescriber documents a significant difference for that patient[4]. That question is covered in semaglutide with B12, and why no generic exists yet is in generic semaglutide.
Quality questions the price does not show
FDA has named specific concerns. It warns that some compounders have used semaglutide salt forms, such as semaglutide sodium and semaglutide acetate, which are different active ingredients from the one in the approved drugs[3]. It has also received reports of adverse events tied to dosing errors, where patients measured the wrong amount from a vial or clinicians miscalculated the dose[3].
A 2024 laboratory study compared 16 injectable follow-on semaglutide products with the originator and found new impurities and impurity patterns in the follow-on products[6]. Every author on that study works for the brand’s maker, and the authors write that the effect of these differences on efficacy and safety remains unknown[6].
A study of the FDA Adverse Event Reporting System from 2018 to 2024 found 707 reports involving compounded products among 81,078 GLP-1 reports[7]. Compounded products had higher reporting odds of hospitalization, with a reporting odds ratio of 2.35 (95% CI 1.94 to 2.83)[7]. Reporting data show which problems get reported, not how often they happen, and the authors state the study was not designed to show cause and effect[7].
Side by side
| Question | Wegovy injection | Compounded semaglutide injection |
|---|---|---|
| Who sets the price | The maker, in its self-pay offer | Each seller, and each seller differently |
| FDA review before sale | Yes, approved with a label | No: compounded drugs are not reviewed for safety, effectiveness or quality |
| What arrives | A box of 4 single-dose pens, one per week | Usually a multi-dose vial and syringes |
| How long an opened supply lasts | Each pen is used once and discarded | FDA says to discard a multi-dose vial 28 days after first use |
| Copay card | Yes, commercially insured patients: pay as little as $25, capped at $100 of savings a month | No maker card applies |
The copay card is a real difference for the commercially insured. The Wegovy Savings Offer lets a patient pay as little as $25 for a one-month fill, subject to a maximum saving of $100[2]; who qualifies is covered in the Wegovy savings card guide. For a compounded seller, the question to ask is which pharmacy makes the product, whether it is semaglutide base rather than a salt, and what the monthly price covers once the fees are added.